Alexander Kiani

Individual Patient Data Meta-analyse of Consensus Molecular Subtypes as Biomarkers of Eerstelijns Behandeling in RAS ...

Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wil...

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A com...

Molecular hyperselection for optimal choice of eerstelijns targeted therapy independent of primary tumor sidedness: A...

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining eerstelijns treatment s...

FOLFOX plus panitumumab of FOLFOX alleen na R0/1 resectie bij RAS-wildtype CRC-levermetastasen: PANTER fase II

SNV's, TMB en MSI bij gemetastaseerd CRC: moleculaire analyse

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab bij gemetastaseerd colorectaal carcinoom: FIRE-3 post-hoc analyse